Dextromethorphan for treatment of complex partial seizures.
We performed a double-blind, crossover, add-on study of the antitussive agent dextromethorphan (DM 120 mg/d) as therapy for seizures on 9 patients suffering from severe complex partial seizures. DM had no significant influence on key laboratory values, nor on anticonvulsant drug levels. Side effects were negligible. Complex partial seizure frequency increased 25% during the DM arm of the study, although this increase was not clinically significant.
Fisher
R S
RS
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Cysyk
B J
BJ
Lesser
R P
RP
Pontecorvo
M J
MJ
Ferkany
J T
JT
Schwerdt
P R
PR
Hart
J
J
Gordon
B
B
D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D003915:Dextromethorphan / Q000627:therapeutic use*; D004311:Double-Blind Method; D004347:Drug Interactions; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007981:Levorphanol / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010865:Pilot Projects; D011897:Random Allocation
D000927:Anticonvulsants; D007981:Levorphanol; D003915:Dextromethorphan